d -Dimer Testing to Determine the Duration of Anticoagulation Therapy
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The optimal duration of oral anticoagulation in patients with idiopathic venous thromboembolism is uncertain. Testing of D-dimer levels may play a role in the assessment of the need for prolonged anticoagulation. METHODS: We performed D-dimer testing 1 month after the discontinuation of anticoagulation in patients with a first unprovoked proximal deep-vein thrombosis or pulmonary embolism who had received a vitamin K antagonist for at least 3 months. Patients with a normal D-dimer level did not resume anticoagulation, whereas those with an abnormal D-dimer level were randomly assigned either to resume or to discontinue treatment. The study outcome was the composite of recurrent venous thromboembolism and major bleeding during an average follow-up of 1.4 years. RESULTS: The D-dimer assay was abnormal in 223 of 608 patients (36.7%). A total of 18 events occurred among the 120 patients who stopped anticoagulation (15.0%), as compared with 3 events among the 103 patients who resumed anticoagulation (2.9%), for an adjusted hazard ratio of 4.26 (95% confidence interval [CI], 1.23 to 14.6; P=0.02). Thromboembolism recurred in 24 of 385 patients with a normal D-dimer level (6.2%). Among patients who stopped anticoagulation, the adjusted hazard ratio for recurrent thromboembolism among those with an abnormal D-dimer level, as compared with those with a normal D-dimer level, was 2.27 (95% CI, 1.15 to 4.46; P=0.02). CONCLUSIONS: Patients with an abnormal D-dimer level 1 month after the discontinuation of anticoagulation have a significant incidence of recurrent venous thromboembolism, which is reduced by the resumption of anticoagulation. The optimal course of anticoagulation in patients with a normal D-dimer level has not been clearly established. (ClinicalTrials.gov number, NCT00264277 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,783
Poort, Sr., Rosendaal, F., Reitsma, P., & Bertina, R. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,079
Heit, J. A., Mohr, D. N., Silverstein, M. D., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.761 · Cited by 1,352
Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D'Angelo, A., Pengo, V., Erba, N., Moia, M., Ciavarella, N., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01109-9 · Cited by 1,333
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Schulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis
Agnelli, G., Prandoni, P., Santamaria, M. G., Bagatella, P., Iorio, A., Bazzan, M., Moia, M., Guazzaloca, G., Bertoldi, A., Tomasi, C., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450302 · Cited by 591
Self-citationO'Neill, D. D., Westerman, D. P., & Sacco, W. (1966) · doi:10.21236/ad0635168 · Cited by 566
Pinede, L., Ninet, J., Duhaut, P., Chabaud, S., Demolombe-Rague, S., Durieu, I., Nony, P., Sanson, C., & Boissel, J.-P. (2001) · Circulation · doi:10.1161/01.cir.103.20.2453 · Cited by 408
Research works printed but not linked: 1
- Kearon C, 2003, CMAJ, 168, 183
Cited by
Items 201–300 of 619
Favaloro, E. J., Cervellin, G., & Lippi, G. (2014) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0034-1384630 · Cited by 29
Predicting the Risk of Recurrent Venous Thromboembolism: Current Challenges and Future Opportunities
Stevens, H., Peter, K., Tran, H. A., & McFadyen, J. D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051582 · Cited by 28
Ethnoracial variations in venous thrombosis: Implications for management, and a call to action
Xu, Y., Siegal, D. M., & Anand, S. S. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15140 · Cited by 28
Prandoni, P., Barbar, S., Milan, M., Vedovetto, V., & Pesavento, R. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.09.005 · Cited by 26
Segna, D., Méan, M., Limacher, A., Baumgartner, C., Blum, M. R., Beer, J. H., Kucher, N., Righini, M., Matter, C. M., Frauchiger, B., et al. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13276 · Cited by 27
Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism
Cosmi, B., & Palareti, G. (2010) · Thrombosis Research · doi:10.1016/s0049-3848(10)70016-5 · Cited by 28
Self-citationNew Trends in Anticoagulation Therapy
SMITH, M. H. D., Wakam, G. K., Wakefield, T. W., & Obi, A. T. (2018) · Surgical Clinics of North America · doi:10.1016/j.suc.2017.11.003 · Cited by 26
“9%.(38, 41) The use of repeat serial lower extremity ultrasound to determine the state of the thrombosed veins has been studied, with the assumption that if the veins are occluded with fibrotic scar tissue, flow will be sluggish and the risk of recurrent VTE elevated.”
BackgroundMinno, M. N. D. D., Calcaterra, I. L., Papa, A., Lupoli, R., Minno, A. D., Maniscalco, M., & Ambrosino, P. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.04.004 · Cited by 29
Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism
Agnelli, G., & Becattini, C. (2013) · Hematology · doi:10.1182/asheducation-2013.1.471 · Cited by 27
Risk Assessment Scores for Cancer-Associated Venous Thromboembolic Disease
Angelini, D. E., & Khorana, A. A. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1597281 · Cited by 29
Legnani, C., Martinelli, I., Palareti, G., Ciavarella, A., Poli, D., Ageno, W., Testa, S., Mastroiacovo, D., Ciammaichella, M. M., Bucherini, E., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219751 · Cited by 25
Self-citationD-dimer testing to determine the duration of anticoagulant therapy
Palareti, G., Cosmi, B., & Legnani, C. (2007) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3282058b94 · Cited by 24
Self-citationÁinle, F. N., & Kevane, B. (2020) · Hematology · doi:10.1182/hematology.2020002268 · Cited by 27
Tetzlaff, E. D., Correa, A. M., Komaki, R. R., Swisher, S. G., Maru, D. M., Ross, W. A., & Ajani, J. A. (2008) · Diseases of the Esophagus · doi:10.1111/j.1442-2050.2008.00829.x · Cited by 24
Barbar, S., Milan, M., Campello, E., Spiezia, L., Piovella, C., Pesavento, R., & Prandoni, P. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-04-0396 · Cited by 26
“Following the demonstration that D-dimer can help stratify the individual risk of recurrent VTE (32-36), a randomised clinical trial showed that in patients in whom anticoagulation was withdrawn because of a negative D-dimer – assessed one month after warfarin discontinuation – the rate of recurrent events is only sli…”
BackgroundGeersing, G., Hendriksen, J. M. T., Zuithoff, N. P. A., Roes, K. C. B., Oudega, R., Takada, T., Schutgens, R. E. G., & Moons, K. G. M. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003142 · Cited by 24
“, “high risk patients”) were randomized to prolonged (intervention) or discontinued anticoagulant treatment (control) [10].”
BackgroundAtherothrombosis and oxidative stress: the connection and correlation in diabetes
Nwose, E. U., Jelinek, H. F., Richards, R. S., Tinley, P., & Kerr, P. G. (2009) · Redox Report · doi:10.1179/135100009x392458 · Cited by 25
Adias, T. C., Jeremiah, Mgbere, O. O., Essien, E. J., & Opiah (2012) · International Journal of Women s Health · doi:10.2147/ijwh.s32655 · Cited by 23
“17 Contrastingly, in this study, no significant changes were observed in the prothrombin time and activated Another significant observation in this study is the progressive rise, up to 600 ng/mL, in the D-dimer concentration during the second and third trimesters of pregnancy.”
Venous Thromboembolic Events in the Rehabilitation Setting
Kelly, B. M., Yoder, B., Tang, C., & Wakefield, T. W. (2010) · PM&R · doi:10.1016/j.pmrj.2010.03.029 · Cited by 24
Management of Deep Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline
Linnemann, B., Beyer‐Westendorf, J., Espinola–Klein, C., Mühlberg, K. S., Müller, O. J., & Klamroth, R. (2024) · Hämostaseologie · doi:10.1055/a-2178-6574 · Cited by 32
Venous Thromboembolism Overview
Battinelli, E. M., Murphy, D. L., & Connors, J. M. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.010 · Cited by 23
Outcomes of genetic testing in adults with a history of venous thromboembolism.
Segal, J. B., Brotman, D. J., Emadi, A., Necochea, A. J., Samal, L., Wilson, L. M., Crim, M. T., & Bass, E. B. (2009) · PubMed Central · Cited by 29
Impact and clinical significance of recurrent venous thromboembolism
Labropoulos, N., Spentzouris, G., Gasparis, A. P., & Meissner, M. H. (2010) · British journal of surgery · doi:10.1002/bjs.7156 · Cited by 25
Balancing risks and benefits of extended anticoagulant therapy for idiopathic venous thrombosis
Kearon, C. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03388.x · Cited by 24
Controversies in the antiphospholipid syndrome: can we ever stop warfarin?
Fonseca, A. G., & D’Cruz, D. P. (2008) · Journal of Autoimmune Diseases · doi:10.1186/1740-2557-5-6 · Cited by 23
Phillippe, H. M., Hornsby, L. B., Eudaley, S. T., Armstrong, E. M., & Bellone, J. M. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014530390 · Cited by 29
Management of acute pulmonary embolism: a contemporary, risk-tailored approach.
Chalikias, G. K., Tziakas, D. N., Stakos, D., & Konstantinides, S. (2010) · PubMed · Cited by 25
Optimal treatment duration of venous thrombosis
Ageno, W., Dentali, F., Donadini, M. P., & Squizzato, A. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12234 · Cited by 21
Overview and assessment of risk factors for pulmonary embolism
Hoo, G. W. S. (2013) · Expert Review of Respiratory Medicine · doi:10.1586/ers.13.7 · Cited by 26
Enfermedad tromboembólica pulmonar. Manejo clínico de la enfermedad aguda y crónica
Torbicki, A. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70186-x · Cited by 22
“Los pacientes con una concentración anormal de dímero D en plasma deben reanudar la anticoagu-lación, dado el riesgo relativamente elevado de re-currencias 110 .”
BackgroundTarango, C., Schulman, S., Betensky, M., & Goldenberg, N. A. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2018.1407241 · Cited by 21
“The PROLONG study assessed the risk of recurrent VTE if patients had an abnormal D-dimer drawn 1 month after cessation of at least 3 months of anticoagulation; those with a positive D-dimer were randomized to either restart or continue off anticoagulation [25].”
BackgroundFei, Y., Zong, G.-Q., Chen, J., & Liu, R. (2015) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615569273 · Cited by 21
Duration of Anticoagulation After Cerebral Venous Sinus Thrombosis
Caprio, F., & Bernstein, R. A. (2011) · Neurocritical Care · doi:10.1007/s12028-011-9661-1 · Cited by 21
“However, long-term anticoagulation was associated with about double the risk of major bleeding, with absolute rate of 1–2% per year (LOE I) [30–35].”
BackgroundState of the art paper Clinical update on pulmonary embolism
Duru, S. A., Keleşoğlu, A., & Ardiç, S. (2013) · Archives of Medical Science · doi:10.5114/aoms.2013.34325 · Cited by 27
Goldenberg, N. A. (2008) · Hematology · doi:10.1182/asheducation-2008.1.236 · Cited by 20
Can I Stop the Warfarin? A Review of the Risks and Benefits of Discontinuing Anticoagulation
Spiess, J. L. (2009) · Journal of Palliative Medicine · doi:10.1089/jpm.2008.0164 · Cited by 20
Nakagawa, K., Watanabe, J., Suwa, Y., Suzuki, S., Ishibe, A., Ota, M., Kunisaki, C., & Endo, I. (2019) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12256 · Cited by 20
Post-Anticoagulant D-Dimer Is a Highly Prognostic Biomarker of COVID-19 Mortality
Song, X., Ji, J., Reva, B. A., Joshi, H. N., Calinawan, A. P., Mazumdar, M., Wisnivesky, J. P., Taioli, E., Wang, P., & Veluswamy, R. R. (2020) · ERJ Open Research · doi:10.1183/23120541.00018-2021 · Cited by 21
“However, persistently elevated or rising D-dimer levels following anticoagulation in COVID-19 patients may signify continued risk of large vessel thrombotic events [16, 17].”
InfluentialPulmonary Embolism and Deep Vein Thrombosis
Hanna, E. B. (2017) · Wiley eBooks · doi:10.1002/9781119233503.ch21 · Cited by 19
Michiels, J. J. (2015) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v4.i1.29 · Cited by 19
Acute pulmonary embolism. Part 2: treatment
van Es, J., Douma, R. A., Gerdes, V. E. A., Kamphuisen, P. W., & Buller, H. R. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.141 · Cited by 19
Nagler, M., Cate, H. T., Prins, M. H., & ten Cate‐Hoek, A. J. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12079 · Cited by 19
Gong, X., Lei, X.-T., Huang, Z., Song, Y., Wang, Q., Qian, J., & Ge, J. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-09991-6 · Cited by 19
Kearon, C., Parpia, S., Spencer, F. A., Baglin, T. P., Stevens, S. M., Bauer, K. A., Lentz, S. R., Kessler, C. M., Douketis, J. D., Moll, S., et al. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.06.023 · Cited by 20
“This finding has led to the proposal that such patients should stop anticoagulant therapy after 3 or 6months and have D-dimer level measured one month later [2,3].”
BackgroundDubois-Silva, Á., Barbagelata-López, C., Mena, Á., Piñeiro-Parga, P., Llinares-García, D., & Castro, S. J. F. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02416-x · Cited by 18
Tripodi, A., Legnani, C., Lemma, L., Cosmi, B., Palareti, G., Chantarangkul, V., & Mannucci, P. M. (2010) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-010-0479-z · Cited by 18
Self-citationPrognostic Significance of Elevated D-Dimer for Survival in Patients with Sarcoma
Raj, S. D., Zhou, X., Bueso-Ramos, C., Ravi, V., PATEL, S. R., Benjamin, R. S., & Vadhan‐Raj, S. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31821d4529 · Cited by 18
“patients 45 21 24 Age, median (range) 39 (16-65) 41 (16-65) 39 (20-62) 0.”
Tchaikovski, S. N., Holmström, M., Rosing, J., Bremme, K., Lärfars, G., & Sonnevi, K. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-04-0254 · Cited by 19
“In contrast to the previous reports (30, 31), we did not find a significant correlation between increased D-dimer and recurrence of VTE.”
BackgroundResultUresandi, F., Monréal, M., García-Bragado, F., Domenech, P., Lecumberri, R., Escribano, P., Zamorano, J. L., Jiménez, S., Ruiz‐Artacho, P., Lozano, F., et al. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2013.10.008 · Cited by 40
Persistent global hypercoagulability in long-term survivors of acute pulmonary embolism
Chow, V., Reddel, C. J., Pennings, G. J., Chung, T., Ng, A. C. C., Curnow, J. L., & Kritharides, L. (2015) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000285 · Cited by 18
Martínez, C., Katholing, A., Folkerts, K., & Cohen, A. T. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13337 · Cited by 18
Unanswered questions in venous thromboembolism
Weitz, J. I. (2009) · Thrombosis Research · doi:10.1016/s0049-3848(09)70135-5 · Cited by 19
“9% of those with a normal D-dimer level [29].”
BackgroundBombardier, C., Villalobos‐Menuey, E., Ruegg, K. A., Hathaway, W. E., Manco‐Johnson, M. J., & Goldenberg, N. A. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.03.030 · Cited by 18
“This hypothesis is supported by the observation that, in idiopathic VTE in adults, a persistently elevated plasma level ofD-dimer (a surrogate marker of hypercoagulability) following a 6 month course of therapeutic anticoagulation significantly increases the risk of recurrent VTE [6].”
BackgroundInfluentialPredicting the risk of recurrent venous thromboembolism
Eischer, L., & Kyrle, P. A. (2013) · Hämostaseologie · doi:10.5482/hamo-13-03-0018 · Cited by 18
“Palareti and co-workers performed the only randomized trial in this setting (50).”
BackgroundDifference in the D-dimer rise between women with singleton and multifetal pregnancies
Yamada, T., Kawaguchi, S., Araki, N., Takeda, M., Nishida, R., Yamada, T., Morikawa, M., & Minakami, H. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.04.029 · Cited by 19
“As D-dimer levels are suggested to be elevated in patients who develop VTE later [13–15], a high baseline D-dimer level is a risk factor for subsequent VTE [13–15].”
BackgroundDiagnosis and Management of Venous Thromboembolism
Minichiello, T., & Fogarty, P. F. (2008) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.12.001 · Cited by 17
Bova, C., Bianco, A., Mascaro, V., & Nobile, C. G. A. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.01.005 · Cited by 18
Miceli, G., Ciaccio, A. M., & Tuttolomondo, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103448 · Cited by 20
“In the PROLONG study, patients with normal D-dimer levels one month after stopping anticoagulation for unprovoked VTE had a significantly lower recurrence rate, allowing for a safe discontinuation and reduced bleeding risk [44].”
Duration of Anticoagulation: Applying the Guidelines and Beyond
Bauer, K. A. (2010) · Hematology · doi:10.1182/asheducation-2010.1.210 · Cited by 18
Aspirin and recurrent venous thromboembolism
Prandoni, P., Noventa, F., & Milan, M. (2013) · Phlebology The Journal of Venous Disease · doi:10.1177/0268355512475040 · Cited by 16
Current Status and Trends in the Treatment of Acute Pulmonary Thromboembolism
Yamada, N., Nakamura, M., & Ito, M. (2011) · Circulation Journal · doi:10.1253/circj.cj-11-1030 · Cited by 17
Konstantinides, S., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D. A., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M. J. C., Kucher, N., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.12.002 · Cited by 25
Lukas, P. S., Neugebauer, A., Schnyder, S., Biasiutti, F. D., Krummenacher, R., Ferrari, M.-L. G., & von Känel, R. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.04.011 · Cited by 18
Predicting the risk of recurrent venous thrombosis: What the future might bring
Lijfering, W. M., Timp, J. F., & Cannegieter, S. C. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14534 · Cited by 21
Sánchez‐Siles, M., Rosa‐Salazar, V., Salazar‐Sánchez, N., & Camacho‐Alonso, F. (2014) · Acta Odontologica Scandinavica · doi:10.3109/00016357.2014.920514 · Cited by 16
for the DULCIS (D-dimer and ULtrasonography in Combination Italian Study) Investigators, Palareti, G., Legnani, C., Antonucci, E., Cosmi, B., Poli, D., Testa, S., Tosetto, A., Ageno, W., Falanga, A., et al. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-019-02216-y · Cited by 16
Self-citationPrevention and treatment of the postthrombotic syndrome
Henke, P. K. (2010) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2010.05.070 · Cited by 16
Recent advances in the management of venous thromboembolism
Ageno, W. (2010) · The Korean Journal of Hematology · doi:10.5045/kjh.2010.45.1.8 · Cited by 16
“In the PROLONG study [11], patients with unprovoked VTE underwent D-dimer testing 1 month after oral anticoagulant treatment discontinuation.”
MethodResultNagler, M., van Kuijk, S. M. J., Cate, H. T., Prins, M. H., & ten Cate‐Hoek, A. J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.655226 · Cited by 17
“All other variables investigated in the cohort study were defined previously (20).”
BackgroundANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism
D’Agostino, C., Zonzin, P., Enea, I., Gulizia, M. M., Ageno, W., Agostoni, P., Azzarito, M., Becattini, C., Bongarzoni, A., Bux, F., et al. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux030 · Cited by 16
Self-citationPulmonary Thromboembolic Disease. Clinical Management of Acute and Chronic Disease
Torbicki, A. (2010) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(10)70168-7 · Cited by 15
Eichinger, S., & Kyrle, P. A. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03383.x · Cited by 15
Contemporary management of pulmonary embolism: the answers to ten questions
Bounameaux, H. M. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02254.x · Cited by 17
D-Dimer Testing in Laboratory Practice*
Tripodi, A. (2012) · Laboratory Medicine Online · doi:10.3343/lmo.2012.2.3.119 · Cited by 14
Self-citationDirect Oral Anticoagulants and the Paradigm Shift in the Management of Venous Thromboembolism
Lim, H. Y., Nandurkar, H. H., & Ho, P. W. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1637750 · Cited by 15
Antonucci, E., Migliaccio, L., Abbattista, M., Caronna, A., Marchi, S. D., Giorgio, A. D., Giulio, R. D., Lerede, T., Garzia, M., Martinelli, I., et al. (2020) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620945792 · Cited by 14
Self-citationNeumann, I., Izcovich, A., Aguilar, R., Basantes, G. L., Casais, P., Colorio, C. C., Guillermo, C., Lázaro, P. P. G., Meillón‐García, L. A., Pereira, J. I., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004267 · Cited by 14
Marcucci, M., Iorio, A., & Douketis, J. D. (2013) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-012-0225-2 · Cited by 15
Self-citationEpidemiology of recurrent venous thrombosis
Ribeiro, D. D., Lijfering, W. M., Barreto, S. M., Rosendaal, F. R., & Rezende, S. M. (2011) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2011007500166 · Cited by 17
“D-dimer testing D-dimer levels have been used as a predictive test for recurrence of venous thrombosis when remaining high after 30 days of discontinuation of oral anticoagulation (64).”
BackgroundMethodPulmonary Embolism Associated with Spontaneous Bilateral Achilles Tendon Rupture
Ramirez, M. A., & Richardson, L. C. (2007) · The Journal of Foot & Ankle Surgery · doi:10.1053/j.jfas.2007.03.014 · Cited by 14
Usefulness of Thrombin Generation
Tripodi, A. (2020) · Hämostaseologie · doi:10.1055/a-1200-0417 · Cited by 14
Self-citationRecurrent venous thromboembolism while on anticoagulant therapy
Thachil, J. V. (2012) · Blood Reviews · doi:10.1016/j.blre.2012.04.002 · Cited by 16
Ames, P. R. J., Margaglione, M., Ciampa, A., Colaizzo, D., Ferrara, F., Iannaccone, L., & VincenzoBrancaccio (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.01.014 · Cited by 14
Tripodi, A., Ageno, W., Barcella, L., Coppola, A., Nisio, M. D., Franchini, M., Marchetti, M., Marcucci, R., Marietta, M., Pignatelli, P., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.70079 · Cited by 13
“More recently, the Prolong randomized interventional clinical trial [24] enrolled patients with a first episode of unprovoked VTE, who had been on VKAs for at least 3 months.”
Self-citationEtiology and Assessment of Hypercoagulability with Lessons from Heparin-Induced Thrombocytopenia
Sniecinski, R. M., Hursting, M. J., Paidas, M. J., & Levy, J. H. (2010) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181ff0f7f · Cited by 13
“Among these, d-dimer is arguably the best studied for routine clinical application, and clinical trial data support its utility for determining the need for prolonged anticoagulation in patients with unprovoked venous thromboembolism.(116,117) Soluble P selectin and measurement of thrombin generation show promise as b…”
BackgroundKhan, F. A., Rahman, A. A., Tritschler, T., Carrier, M., Kearon, C., Weitz, J. I., Schulman, S., Couturaud, F., Becattini, C., Agnelli, G., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1690-8728 · Cited by 18
“Kearon et al. 1999 + + + + + + 6 Agnelli et al. 2001 + + + + + + 6 Pinede et al. 2001 + + + + + + 6 Agnelli et al. 2003 + + + + + + 6 Palareti et al. 2006 + + + + + + 6 Schulman et al. 2006 + + + + + + 6 Prandoni et al. 2009 + + + + + + 6 Bauersachs et al. 2010 + + + + + + 6 Becattini et al.2012 +…”
InfluentialSelf-citationNew diagnostic strategies for pulmonary embolism
Kyrle, P. A., & Eichinger, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60572-3 · Cited by 13
Kearon, C. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0573-x · Cited by 13
“Long-term anticoagulant therapy was associated with about a doubling of the frequency of major bleeding, with an absolute rate of major bleeding of 1–2% per year [16, 23, 29, 34].”
BackgroundMethodResultInfluentialTraitement du syndrome des anticorps antiphospholipides
Saadoun, D., Pietté, J. C., Wahl, D. G., & Costedoat-Chalumeau, N. (2012) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2012.01.007 · Cited by 12
Acute and long term management of pulmonary embolism
Torbicki, A. (2010) · Heart · doi:10.1136/hrt.2008.153957 · Cited by 12
“An abnormal level of D-dimer assessed 1 month after stoppingVKAwas highly predictive of a high recurrence rate, which can be successfully abolished by continued treatment.(17) Unfortunately, a negative result of a D-dimer test 1 month after a discontinuation attempt does not guarantee safe withholding of secondary pre…”
BackgroundHass, B., Pooley, J., Harrington, A. E., Clemens, A., & Feuring, M. (2012) · Thrombosis Journal · doi:10.1186/1477-9560-10-24 · Cited by 12
“The most strongly implicated are active cancer, increased plasma fibrin D-dimer, male sex, increasing patient age, increasing body mass index, lupus anticoagulant, antiphospholipid antibody, and protein C or protein S deficiency [4,16,36-41].”
BackgroundA Clinical Perspective of Venous Thromboembolism
Moll, S. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.162818 · Cited by 12
Lobastov, K. V., Ryzhkin, V., Vorontsova, A., Schastlivtsev, I., Barinov, V., Laberko, L. A., & Rodoman, G. V. (2018) · International Angiology · doi:10.23736/s0392-9590.18.03997-4 · Cited by 13
Agrawal, V., & Kim, E. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1111-2 · Cited by 15
Advances in the management of venous thromboembolism
Schulman, S. (2012) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2012.06.003 · Cited by 13
Li, A., Khatib, R., Lopes, L. C., Aloweni, F. B. A. B., Lu, L., He, Q., Wu, J., Zhang, P., Tang, Y., Pavalagantharajah, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015371 · Cited by 14
Clinical Application of Fibrinolytic Assays
Pepperell, D., Morel‐Kopp, M., & Ward, C. (2014) · InTech eBooks · doi:10.5772/57316 · Cited by 13
“The recurrent VTE rate was demonstrated to be significantly less in those who had restarted anticoagulation [76].”
BackgroundClinical decision rules in venous thromboembolism
Gal, G. L., Carrier, M., & Rodger, M. A. (2012) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2012.06.001 · Cited by 13
Steinbrecher, O., Šinkovec, H., Eischer, L., Kyrle, P. A., & Eichinger, S. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.11.015 · Cited by 11
Reitter, S. E., Laczkovics, C., Waldhoer, T., Mayerhofer, M., Vutuc, C., & Pabinger, I. (2010) · Haematologica · doi:10.3324/haematol.2009.017616 · Cited by 12
Metadata
- Authors
- Palareti, G., Cosmi, B., Legnani, C., Tosetto, A., Brusi, C., Iorio, A., Pengo, V., Ghirarduzzi, A., Pattacini, C., Testa, S., Lensing, A. W. A., & Tripodi, A.
- Affiliations
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Ospedale San Bortolo (IT)
- University of Perugia (IT)
- Azienda Ospedale - Università Padova (IT)
- Santa Maria Nuova Hospital (IT)
- Istituti Ospitalieri di Cremona (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-26
- Volume
- 355
- Issue
- 17
- Pages
- 1780-1789
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2047986798
- Cited by
- 622
- References
- 25
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 12 · 2023: 11 · 2022: 14 · 2021: 16 · 2020: 34 · 2019: 22 · 2018: 20 · 2017: 19 · 2016: 40 · 2015: 41 · 2014: 40 · 2013: 38 · 2012: 53
- FWCI
- 35.51
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
- Keywords
- D-dimer, anticoagulation duration, venous thromboembolism, deep vein thrombosis, pulmonary embolism, vitamin K antagonists, recurrence, major bleeding, unprovoked thrombosis, anticoagulation resumption
- MeSH terms
- Acenocoumarol, Adult, Aged, Aged, 80 and over, Anticoagulants, Antithrombins, Drug Administration Schedule, Fibrin Fibrinogen Degradation Products, Follow-Up Studies, Hemorrhage, Humans, Middle Aged, Prospective Studies, Pulmonary Embolism, Recurrence, Ultrasonography, Vitamin K, Warfarin, Proportional Hazards Models, Survival Analysis, Antiphospholipid Syndrome, Venous Thrombosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.